Header and Body 2

Problem Addressed

Large data sets of mutations, gene expression, and protein expression have been generated to understand the biology and progression of cancer with the hopes of identifying ways to treat cancer. However, understanding the role of ECM in disease progression using ECM as a way to target cancer has been mostly limited. This is because ECM proteins are insoluble and are crosslinked, thus, are intractable for large scale protein analysis. The current invention utilizes recently developed proteomic methods to identify ECM signatures associated with cancer and its progression, which can be used to diagnose, prognose, and treat cancer.